Tyra Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by Tyra Biosciences, Inc. on June 13, 2022. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol TYRA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Directors: Three Class I directors were elected for a three-year term expiring at the 2025 Annual Meeting.
- Todd Harris, Ph.D.: 30,052,192 votes For; 409,225 Withheld; 1,090,853 Broker Non-Votes.
- Nina Kjellson: 30,054,242 votes For; 407,175 Withheld; 1,090,853 Broker Non-Votes.
- Siddarth Subramony, Ph.D.: 30,057,150 votes For; 404,267 Withheld; 1,090,853 Broker Non-Votes.
- Ratification of Auditors: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified.
- 31,551,343 votes For; 0 Against; 927 Abstain; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the three-year term for the newly elected Class I directors.
- Verification of the high level of broker non-votes (1,090,853) regarding the director elections.
- Confirmation that Ernst & Young LLP will serve as the auditor for the fiscal year ending December 31, 2022.